Experience with Sulperacef Used in the Treatment of Destructive Abdominal Diseases

Abstract

Objective: to study the clinical efficacy of cefoperazone/sulbactam (Sulperacef, ABOLmed, Russia) in the treatment of acute surgical abdominal diseases. Subjects and methods. A study group included 31 patients with acute surgical abdominal diseases who took cefoperazone/sulbactam (sulperacef), 8 g/day, as an agent of empirical therapy. A control group comprised 42 patients treated in an intensive care unit (ICU) in 2005. This group received the traditional treatment regimen: cefotaxime (6—8 g/day) + amikacin (15 mg/kg/day) + metronidazole (1.5 g/day). The efficiency of antibiotic therapy was evaluated by the sepsis criteria (R. C. Bone): body temperature, leukocytes, heart rate, a need for respiratory support. In addition, the length of ICU stay, mortality, and a need for antibiotic switching were also taken into account. Results. The clinical effect of sulperacef was achieved in 22 out of the 31 patients given the agent. The duration of a course of sulperacef varied from 4 to 15 days (mean 7.7 days). On therapy day 5, the study group patients showed a reduction in the count of leukocytes from 12.15×109/l to 9.7×109/l whereas in the control group leukocytes were 13.43×109/l (p<0.05). The study group displayed a less significant temperature reaction on days 3 and 9 than in the controls (p<0.05). Tachycardia was less pronounced on day 3 (p<0.05). Conclusion. Cefoperazone/sulbactam (sulperacef) may be the drug of choice for starting empirical antibiotic therapy in patients with acute surgical abdominal diseases in ICU conditions.